MoonLake Immunotherapeutics (MLTX) Capital Expenditures Growth (3y) (2024 - 2025)
Powered by 
Analysis
MoonLake Immunotherapeutics (MLTX) Capital Expenditures Growth (3y) (2024 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 23.48% |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 63.07% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -45.93% |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | -40.95% |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 29.63% |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 60.74% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 27.08% |
| 10 | MoonLake Immunotherapeutics | 1.10 Bn | 565.05 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | -693.70% |
| Mar 31, 2025 | 373.35% |
| Dec 31, 2024 | 51.40% |
| Sep 30, 2024 | 124.61% |